{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:06Z","timestamp":1790686206436,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    The experience of patients with mantle cell lymphoma (MCL) in community oncology practices, including reasons for treatment discontinuation, is sparse. This retrospective study sought to elucidate treatment patterns and outcomes of patients with MCL treated with ibrutinib in the community setting. Patients were identified from the US Oncology Network electronic medical records database, iKnowMed\n                    <jats:sup>TM<\/jats:sup>\n                    , between 1 November 2013 and 31 October 2016. Descriptive analysis was performed to describe the demographic and clinical characteristics of the population. Kaplan\u2013Meier estimates were performed to determine clinical outcomes. A Cox proportional hazards model was used to identify predictors of survival. Of the 1914 patients identified with MCL, 159 were treated with ibrutinib. The median age was 71\u00a0years and the majority were male (76%) and Caucasian (89%). The overall discontinuation rate was 83\u00b76%; the most common reasons were progression (35%) and toxicities (25\u00b76%). The median overall survival and progression\u2010free survival was 25\u00b782\u00a0months (95% confidence interval [CI] 19\u00b794, NR) and 19\u00b755\u00a0months (95% CI 16\u00b752, 24\u00b728) respectively. In multivariate modelling, patient age was predictive of survival (hazard ratio 1\u00b7041,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00\u00b70186). Ibrutinib was temporarily reduced in 16\u00b74% (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a026) and held in 30\u00b72% (\n                    <jats:italic>n\u00a0<\/jats:italic>\n                    =\u00a048), primarily due to toxicity 66\u00b77% (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a032). Survival data showed similarities between community oncology practices and clinical trials.\n                  <\/jats:p>","DOI":"10.1111\/bjh.16922","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T12:59:47Z","timestamp":1603457987000},"page":"737-746","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study"],"prefix":"10.1111","volume":"192","author":[{"given":"Jeff","family":"Sharman","sequence":"first","affiliation":[{"name":"The US Oncology Network\/McKesson Specialty Health Woodlands TX USA"},{"name":"Willamette Valley Cancer Institute and Research Center Eugene OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaum M.","family":"Kabadi","sequence":"additional","affiliation":[{"name":"AstraZeneca Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-4273","authenticated-orcid":false,"given":"Jamyia","family":"Clark","sequence":"additional","affiliation":[{"name":"The US Oncology Network\/McKesson Specialty Health Woodlands TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5699-4644","authenticated-orcid":false,"given":"David","family":"Andorsky","sequence":"additional","affiliation":[{"name":"The US Oncology Network\/McKesson Specialty Health Woodlands TX USA"},{"name":"Rocky Mountain Cancer Centers Boulder CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Leukemia and Lymphoma Society.Mantle Cell Lymphoma Facts[Internet].2019[updated 1 November 2019]. Available from:http:\/\/www.lls.org\/sites\/default\/files\/file_assets\/FS4_MCL_Facts_Rev.pdf. accessed July 20 2020"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25215"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"e_1_2_7_5_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology.B\u2010Cell Lymphomas. Version 2.2020 [Internet]. 2020 [updated 9 July 2020]. Available from:http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b\u2010cell.pdfaccessed July 20 2018."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_2_7_7_1","unstructured":"US Food and Drug Administration.FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage[Internet].2019b[updated 14 November 2019]. Available from:https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010therapy\u2010treat\u2010patients\u2010relapsed\u2010and\u2010refractory\u2010mantle\u2010cell\u2010lymphoma\u2010supported\u2010clinical. accessed July 20 2020."},{"key":"e_1_2_7_8_1","first-page":"135","article-title":"Velcade (Bortezomib) receives 2 new fda indications: for retreatment of patients with multiple myeloma and for first\u2010line treatment of patients with mantle\u2010cell lymphoma","volume":"8","author":"Raedler L","year":"2015","journal-title":"Am Health Drug Benefits."},{"key":"e_1_2_7_9_1","first-page":"808","article-title":"Ibrutinib approved for the treatment of mantle cell lymphoma","volume":"11","author":"Small S","year":"2013","journal-title":"Clin Adv Hematol Oncol."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2015.004929"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0353"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1195254"},{"key":"e_1_2_7_15_1","first-page":"6","article-title":"Validation of the social security death index (SSDI): an important readily\u2010available outcomes database for researchers","volume":"9","author":"Quinn J","year":"2008","journal-title":"West J Emerg Med."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15170"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2380"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14870"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16922","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T11:23:25Z","timestamp":1693653805000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/bjh.16922"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16922","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"assertion":[{"value":"2020-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}